ArticleOncotarget2018
ADH1B promotes mesothelial clearance and ovarian cancer infiltration.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- ADH1B Gene Promotes Gastric Cancer Tumorigenesis and its Cisplatin Resistance through the EMT Pathway.Current cancer drug targets · 2026Article
- High-grade serous carcinoma of the fallopian tube in a young woman with chromosomal 4q abnormality: A case report.World journal of clinical cases · 2024Article
- A Recipe for Successful Metastasis: Transition and Migratory Modes of Ovarian Cancer Cells.Cancers · 2024Review
- DFASGCNS: A prognostic model for ovarian cancer prediction based on dual fusion channels and stacked graph convolution.PloS one · 2024Article
- Identification of a short, single site matriglycan that maintains neuromuscular function in the mouse.bioRxiv : the preprint server for biology · 2023Article
- Article
- Omentum provides a special cell microenvironment for ovarian cancer.Cancer reports (Hoboken, N.J.) · 2023Review
- Identification of copper metabolism-related subtypes and establishment of the prognostic model in ovarian cancer.Frontiers in endocrinology · 2023Article
- Article
- Metabolic Alterations and WNT Signaling Impact Immune Response in HGSOC.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Identification of Potential Biomarkers and Small Molecule Drugs for Cutaneous Melanoma Using Integrated Bioinformatic Analysis.Frontiers in cell and developmental biology · 2022Article
- The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination.Frontiers in endocrinology · 2022Review
- Topological defects in the mesothelium suppress ovarian cancer cell clearance.APL bioengineering · 2021Article
- Effects of CXCL12 isoforms in a pancreatic pre-tumour cellular model: Microarray analysis.World journal of gastroenterology · 2021Article
- Comparison of the Fatty Acid Metabolism Pathway in Pan-Renal Cell Carcinoma: Evidence from Bioinformatics.Analytical cellular pathology (Amsterdam) · 2021Article
- Immune infiltration and prognostic and diagnostic use of LGALS4 in colon adenocarcinoma and bladder urothelial carcinoma.American journal of translational research · 2021Article
- Identification and validation of a prognostic index based on a metabolic-genomic landscape analysis of ovarian cancer.Bioscience reports · 2020Article
- Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance.Cancer research · 2020Article
- Deep learning-based ovarian cancer subtypes identification using multi-omics data.BioData mining · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
Primary debulking surgery followed by adjuvant chemotherapy is the standard treatment for ovarian cancer. Residual disease after primary surgery is associated with poor patient outcome. Previously, we discovered ADH1B to be a molecular biomarker of residual disease. In the current study, we investigated the functional role of ADH1B in promoting ovarian cancer cell invasiveness and contributing to residual disease. We discovered that ADH1B overexpression leads to a more infiltrative cancer cell phenotype, promotes metastasis, increases the adhesion of cancer cells to mesothelial cells, and increases extracellular matrix degradation. Live cell imaging revealed that ADH1B-overexpressing cancer cells efficiently cleared the mesothelial cell layer compared to control cells. Moreover, gene array analysis revealed that ADH1B affects several pathways related to the migration and invasion of cancer cells. We also discovered that hypoxia increases ADH1B expression in ovarian cancer cells. Collectively, these findings indicate that ADH1B plays an important role in the pathways that promote ovarian cancer cell infiltration and may increase the likelihood of residual disease following surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.